Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Enables DNA-binding transcription factor activity; double-stranded DNA binding activity; and sequence-specific DNA binding activity. Acts upstream of or within several processes, including hemopoiesis; regulation of gene expression; and regulation of primitive erythrocyte differentiation. Predicted to be active in nucleus. Is expressed in several structures, including ball; cardiovascular system; hematopoietic cell; hematopoietic system; and mesoderm. Human ortholog(s) of this gene implicated in several diseases, including X-linked recessive disease (multiple); bone marrow cancer (multiple); colon adenocarcinoma; depressive disorder; and myeloid leukemia associated with Down Syndrome. Orthologous to human GATA1 (GATA binding protein 1). [provided by Alliance of Genome Resources, Feb 2025]